The prevention and management of ocular surface infections is still one of the great challenges for ophthalmologists. The spread of antimicrobial resistance makes it necessary to use antiseptic substances with a broad antimicrobial spectrum. Polyhexamethylene biguanide hydrochloride (Polyhexanide, PHMB) is a broad-spectrum antiseptic with excellent tolerance and a low-risk profile. Its physicochemical action on the phospholipid membrane and DNA replication or repair mechanism, prevents or impedes the development of resistant bacterial strains. PHMB revealed its effective against numerous organisms like viruses, Gram-negative and Gram-positive bacteria, and fungi. Polyhexanide is commonly used as preservative in commercially available disinfecting solutions for contact lens care and in ophthalmic formulations at different concentrations ranging from 1 µg/ml to 50 µg/ml. The administration of 0.02% (200 µg/ml) PHMB is often the first-line therapy of Acanthamoeba keratitis. However, to date, only one close-out randomized controlled study tested the efficacy of 0.02% PHMB in Acanthamoeba keratitis and a phase III study is still ongoing. This paper reviews the antiseptic agent PHMB, focusing on biochemical mechanisms, safety profile and applications in ophthalmology.
RoseFLSwainG. Polymeric Diguanides. Great Britain Patent 702,268, 13 January 1954.
2.
MashatBH. Polyhexamethylene biguanide hydrochloride: features and applications. British Journal of Environmental Sciences2016; 4: 49–55.
3.
CazzanigaASerraltaVDavisS,et al.The effect of an antimicrobial gauze dressing impregnated with 0.2-percent polyhexamethylene biguanide as a barrier to prevent pseudomonas aeruginosa wound invasion. Wounds-compend. Clin Res Pract2002; 14: 169–176.
4.
PayneJDKudnerDW. A durable antiodor finish for cotton textiles. Text Chem Color1996; 28: 28–30.
5.
KusnetsovJMTulkkiAIAhonenHE,et al.Efficacy of three prevention strategies against legionella in cooling water systems. J Appl Microbiol1997; 82: 763–768.
6.
CoxNABaileyJSBerrangME. Bactericidal treatment of hatching eggs. I. Chemical immersion treatments and salmonella. J Appl Poult Res1998; 7: 347–350.
7.
CoxNABerrangMEBuhrRJ,et al.Bactericidal treatment of hatching eggs. II. Use of chemical disinfectants with vacuum to reduce salmonella. J Appl Poult Res1999; 8: 321–326.
8.
RosinMWelkABernhardtO,et al.Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque. J Clin Periodontol2001; 28: 1121–1126.
9.
RosinMWelkAKocherT,et al.The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol2002; 29: 392–399.
10.
HitiKWalochnikJHaller-SchoberEM,et al.Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Br J Ophthalmol2002; 86: 144–146.
11.
ZambelliAMBrothersKMHuntKM,et al.Diffusion of antimicrobials across silicone hydrogel contact lenses. Eye Contact Lens2015; 41: 277–280.
12.
BouattourYChennellPWasiakM,et al.Stability of an ophthalmic formulation of polyhexamethylene biguanide in gamma-sterilized and ethylene oxide sterilized low density polyethylene multidose eyedroppers. PeerJ2018; 6: e4549.
13.
GentileAGerliSDi RenzoGC. A new non-invasive approach based on polyhexamethylene biguanide increases the regression rate of HPV infection. BMC Clin Pathol2012; 12: 17.
14.
KrebsFCMillerSRFergusonML,et al.Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother2005; 59: 438–445.
15.
PassicSRFergusonMLCataloneBJ, et al.Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother2010; 64: 723–732.
16.
YanaiRUedaKNishidaT,et al.Effects of ionic and surfactant agents on the antimicrobial activity of polyhexamethylene biguanide. Eye & Contact Lens: Science & Clinical Practice2011; 37: 85–89.
17.
MessickCRPendlandSLMoshirfarM, et al.In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis. J Antimicrob Chemother1999; 44: 297–298.
18.
KoburgerTHübnerNOBraunM,et al.Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother2010; 65: 1712–1719.
19.
Petrou-BinderS. PHMB-containing antiseptics ‘may offer alternative' to iodine perioperative agents, say researchers. Available at: http://www.escrs.org/eurotimes/April2003/phmb.aspù. (accessed on 03 December 2021).
20.
HansmannFKramerAOhgkeH,et al.Polyhexamethylbiguanid (PHMB) zur präoperativen antisepsis bei cataract operation. Ophthalmologe2004; 101: 377–383.
Carrijo-CarvalhoLCSant'anaVPForondaAS,et al.Therapeutic agents and biocides for ocular infections by free-living amoebae of Acanthamoeba genus. Surv Ophthalmol2017; 62: 203–218.
23.
Community Research and Development Information Service (CORDIS). Community Research and Development Information Service (CORDIS) PHMB eye drops for treating Acanthamoeba ocular infections. 2015. Available at. 2015: http://cordis.europa.eu/result/rcn/159866_en.html. (accessed on 03 December 2021).
AllenMJWhiteGFMorbyAP. The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide. Microbiology (Reading)2006; 152: 989–1000.
26.
KaehnK. Polihexanide: a safe and highly effective biocide. Skin Pharmacol Physiol2010; 23: 7–16.
FjeldHLingaasE. Polyhexanide - safety and efficacy as an antiseptic. Tidsskr Nor Laegeforen2016; 136: 707–711.
29.
MarisP. Modes of action of disinfectants. Rev sci tech Off int Epiz1995; 14: 47–55.
30.
KhunkittiWHannACLloydD,et al.X-ray microanalysis of chlorine and phosphorus content in biguanide-treated Acanthamoeba castellanii. J Appl Microbiol1999; 86: 453–459.
31.
BroxtonPWoodcockPMGilbertP. A study of the antibacterial activity of some polyhexamethylene biguanides towards Escherichia coli ATCC 8739. J Appl Bacteriol1983; 54: 345–353.
32.
ElszteinCde MenezesJAde MoraisMA. Polyhexamethyl biguanide can eliminate contaminant yeasts from fuel-ethanol fermentation process. J. Ind.Microbiol. Biotechnol2008; 35: 967–973.
33.
GilbertPPembertonDWilkinsonDE. Barrier properties of the gram-negative cell envelope towards high molecular weight polyhexamethylene biguanides. J Appl Bacteriol1990; 69: 585–592.
34.
AllenMJMorbyAPWhiteGF. Cooperativity in the binding of the cationic biocide polyhexamethylene biguanide to nucleic acids. Biochem Biophys Res Commun2004; 318: 397–404.
35.
ChinderaKMahatoMSharmaAK, et al.The antimicrobial polymer PHMB enters cells and selectively condenses bacterial chromosomes. Sci Rep2016; 6: 23121.
36.
Sowlati-HashjinSPaola CarbonePKarttunenM. Insights into the polyhexamethylene biguanide (PHMB) mechanism of action on bacterial membrane and DNA: a molecular dynamics study. J Phys Chem B2020; 12: 4487–4497.
37.
BjarnsholtTKirketerp-MøllerKJensenPØ,et al.Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen2008; 16: 2–10.
38.
VontobelSFAbad-VillarEMKaufmannC,et al.Corneal penetration of polyhexamethylene biguanide and chlorhexidine digluconate. J Clin Exp Ophthalmol2015; 6: 3.
39.
McDonnellGRussellAD. Antiseptics and disinfectants: activity, action, and resistance [published correction appears in clin microbiol rev 2001 jan;14(1):227]. Clin Microbiol Rev1999; 12: 147–179.
40.
BroxtonPWoodcockPMHeatleyF,et al.Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol1984; 57: 115–124.
41.
SauerbreiASchackeMGluckB,et al.Validation of biocides against duck hepatitis B virus as a surrogate virus for human hepatitis B virus. J Hosp Infect2006; 64: 358–365.
42.
MaillardJY. Virus susceptibility to biocides: an understanding. Rev Med Microbiol2001; 12: 63–74.
PintoFMaillardJYDenyerSP. Effect of surfactants, temperature, and sonication on the virucidal activity of polyhexamethylene biguanide against the bacteriophage MS2. Am J Infect Control2010; 38: 393–39820006410.
45.
JohnsonWBoyerIZhuJ, et al.Safety assessment of polyaminopropyl biguanide (polyhexamethylene biguanide hydrochloride) as used in cosmetics. Int J Toxicol2020; 39: 26S–73S.
46.
Commission Regulation (EU). No 944/2013 of 2 October 2013 amending, for the purposes of its adaptation to technical and scientific progress, regulation (EC) no 1272/2008 of the European parliament and of the council on classification, labelling and packaging of substances and mixturesText with EEA relevance. Off J Eur Union2013; L261/5: 5–22.
47.
Commission Regulation (EU). 2019/831 Of 22 may 2019 amending annexes II, III and V to regulation (EC) no 1223/2009 of the European parliament and of the council on cosmetic products (text with EEA relevance.). Off J Eur Union2019; L137/29: 29–63.
LeysenJGoossensALambertJ,et al.Polyhexamethylene biguanide is a relevant sensitizer in wet wipes. Contact Dermatitis2014; 70: 316–328.
52.
BervoetsAAertsO. Polyhexamethylene biguanide in wound care products: a non-negligible cause of peri-ulcer dermatitis. Contact Dermatitis2015; 74: 52–65.
53.
FindlaASerranoCPunzalanS, et al.Increased peritoneal dialysis exit site infections using topical antiseptic polyhexamethylene biguanide compared to mupirocin: results of a safety interim analysis of an open-label prospective randomized study. Antimicrob Subst Chemother2013; 57: 2026–2038.
54.
OlivieriJEigenmannPAHauserC. Severe anaphylaxis to a new disinfectant: polyhexanide, a chlorhexidine polymer. Schweiz Med Wochenschr1998; 128: 1508–1511.
55.
KautzOSchumannHDegerbeckF,et al.Severe anaphylaxis to the antiseptic polyhexanide. Allergy2010; 65: 1068–1070.
56.
SchunterJAStockerBBrehlerR. A case of severe anaphylaxis to polyhexanide: cross-reactivity between biguanide antiseptics. Int Arch Allergy Immunol2017; 173: 233–236.
57.
Pastor-NietoMAGonzalez-MunozPPerez-MesoneroR, et al.Allergic contact dermatitis caused by poly(hexamethylene) biguanide hydrochloride in contact lens care solutions. Contact Dermatitis2017; 76: 357–381.
58.
ChristiansenRPalmorkKH. Distribution and elimination of [14C] in saithe (Pollachius virens L.) after application of a single dose of [14C] polyhexamethylene hydrochloridbi-guanide. Bull Environ Contam Toxicol1996; 36: 121–128.
59.
BrattHHathwayDE. Characterization of the urinary polymer-related material from rats given poly[biguanide-1,5-diylhexa-methylene hydrochlorid]. Macromol Chem Phys1976; 177: 2591–2605.
60.
KramerADaeschleinGKammerlanderG, et al.Consensus paper on wound antisepsis. Zentralbl für Wundheilung2004; 9: 110–120.
DissemondJGerberVKramerA,et al.Practice-oriented expert recommendation for the treatment of critically colonised and local infected wounds using polihexanide. Zeitschrift für Wundheilung2009; 14: 20–26.
Safety Assessment of Polyaminopropyl Biguanide as Used in Cosmetics. Status: Scientific Literature Review for Public Comment. Cosmetic Ingredient Review, Washington DC, USA. 2017.
Enviromental Protection Agency. Poly(hexamethylenebiguanide) hydrochloride. Human Health Scoping Document for the Registration Review. June 2012.
67.
KramerABehrens-BaumannW. Prophylactic use of topical anti-infectives in ophthalmology. Ophthalmologica1997; 211: 68–76.
68.
DuguidIGDartJKMorletN,et al.Tuft S outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology1997; 104: 1587–1592.
69.
ZhangXMarchettiCLeeJ, et al.The impact of lens care solutions on corneal epithelial changes during daily silicone hydrogel contact lens wear as measured by in vivo confocal microscopy. Cont Lens Anterior Eye2017; 40: 33–41.
70.
BrightFVMercheaMMKrautND,et al.A preservative-andfluorescein interaction model for benign multipurpose solution-associated transient corneal hyperfluorescence. Cornea2012; 31: 1480–1488.
71.
WilsonGLadagePMCavanaghHD. The epithelium in extended wear. In: SweeneyDF (ed.) Silicone hydrogels: continuous wear contact lens. Oxford, United Kingdom: Butterworth-Heinemann, 2004, pp.28–54.
72.
WoodsJJonesLW. Pilot study to determine the effect of lens and eye rinsing on solution-induced corneal staining (SICS). Optom Vis Sci2016; 93: 1218–1227.
73.
SchneiderS. The appearance of hyper-reflective superficial epithelial cells observed using in vivo confocal microscopy. PhD thesis, University of Waterloo, Waterloo, ON, 2010.
74.
GarofaloRJDassanayakeNCareyC,et al.Corneal staining and subjective symptoms with multipurpose solutions as a function of time. Eye Contact Lens2005; 31: 166–174.
75.
ChoyCKMChoPBoostMV. Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Clin Exp Optom2012; 95: 198–206.
76.
JonesLMacDougallNSorbaraLG. Asymptomatic corneal staining associated with the use of balafilcon silicone-hydrogel contact lenses disinfected with a polyaminopropyl biguanide-preserved care regimen. Optom Vis Sci2002; 79: 753–761.
77.
AndraskoGRyenK. Corneal staining and comfort observed with traditional and silicone hydrogel lenses and multipurpose solution combinations. Optometry2008; 79: 444–454.
78.
YoungGKeirNHuntC,et al.Clinical evaluation of long-term users of two contact lens care preservative systems. Eye Contact Lens2009; 35: 50–58.
79.
GorbetMPetersonRMcCannaD,et al.Human corneal epithelial cell shedding and fluorescein staining in response to silicone hydrogel lenses and contact lens disinfecting solutions. Curr Eye Res2014; 39: 245–256.
80.
DiecJEvansVETiliaD,et al.Comparison of ocular comfort, vision, and SICS during silicone hydrogel contact lens daily wear. Eye Contact Lens2012; 38: 2–6.
81.
BandamwarKLGarrettQCheungD,et al.Onset time course of solution induced corneal staining. Cont Lens Anterior Eye2010; 33: 199–201.
82.
WoodsJKeirNJonesL. Solution induced corneal staining (SICS): symptoms and staining patterns. Optom Vis Sci2012; 89: E-abstract 125625.
JalbertICarntNNaduvilathTJ,et al.The relationship between solution toxicity, corneal inflammation and ocular comfort in soft contact lens daily wear. Invest Ophthalmol Vis Sci2006; 47: E-abstract 2412.
87.
CarntNJalbertIStrettonS,et al.Solution toxicity in soft contact lens daily wear is associated with corneal inflammation. Optom Vis Sci2007; 84: 309Y15.
88.
Santodomingo-RubidoJMoriOKawaminamiS. Cytotoxicity and antimicrobial activity of six multipurpose soft contact lens disinfecting solutions. Ophthalmic Physiol Opt2006; 26: 476–482.
89.
WillcoxMDPPhillipsBOzkanJ,et al.Interactions of lens care with silicone hydrogel lenses and effect on comfort. Optom Vis Sci2010; 87: 839–846.
90.
ImayasuMShiraishiAOhashiY,et al.Effects of multipurpose solutions on corneal epithelial tight junctions. Eye Contact Lens2008; 34: 50–55.
91.
MencucciRFavuzzaEBottinoP, et al.A new ophthalmic formulation containing antiseptics and dexpanthenol: in vitro antimicrobial activity and effects on corneal and conjunctival epithelial cells. Exp Eye Res2020; 201: 108269.
92.
KhanNA. Acanthamoeba – Biology and Pathogenesis. Caister Academic Press: Norfolk, Great Britain, 290 p. 2009.
SunXZhangYLiR,et al.Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology2006; 113: 412–441.
95.
ODAK Consortium. Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects. Protocol Number: ODAK Phase I (042/SI); NCT02506257; 04 December 2015.
96.
PapaVvan der MeulenIRotteyS,et al.Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. Br J Ophthalmol2020; 106(2): 190–196.
97.
XuYHeYZhouL,et al.Effects of contact lens solution disinfectants against filamentous fungi. Optom Vis Sci2014; 91: 1440–1445.
98.
KramerA. Stellenwert der infektionsprophylaxe und -therapie mit lokalen antiinfektiva. In: KramerAWendtMWernerHP (eds) Möglichkeiten und perspektiven der klinischen antiseptik. Wiesbaden: mhp, 1995, pp.15–25.
99.
MillerMJCallahanDEMcGrathD,et al.Disinfection efficacy of contact lens care solutions against ocular pathogens. CLAO J2001; 27: 16–22.
100.
AbjaniFKhanNAJungSY,et al.Status of the effectiveness of contact lens disinfectants in Malaysia against keratitis-causing pathogens. Exp Parasitol2017; 183: 187–193.
ShoffMEJoslinCETuEY,et al.Efficacy of contact lens systems against recent clinical and tap water Acanthamoeba isolates. Cornea2008; 27: 713–719.
104.
BoostMVShiG-SLaiS,et al.Amoebicidal effects of contact lens disinfecting solutions. Optom Vis Sci2012; 89: 44–51.
105.
JohnstonSPSriramRQvarnstromY, et al.Resistance of Acanthamoeba cysts to disinfection in multiple contact lens solutions. J Clin Microbiol2009; 47: 2040–2045.
106.
Szczotka-FlynnLBImamuraYChandraJ,et al.Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. Cornea2009; 28: 918–926.
107.
RomanowskiEGYatesKAO’ConnorKE,et al.Evaluation of polyhexamethylene biguanide (PHMB) as a disinfectant for adenovirus. JAMA Ophthalmol2013; 131: 495–498.
DaeschleinGAssadianOBruckJC,et al.Feasibility and clinical applicability of polihexanide for treatment of second-degree burn wounds. Skin Pharmacol Physiol2007; 20: 292–296.
110.
SzkołudaPKarpińskiT. Polyhexanide (PHMB) – properties and applications in medicine. Eur J Biol Res2020; 10: 225–231.
111.
LarkinDFPKilvingtonSDartJKG. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology 1992; 99(2): 185–191.
112.
MaycockNJRJayaswalR. Update on Acanthamoeba keratitis: diagnosis, treatment, and outcomes. Cornea2016; 35: 713–720.
113.
KilvingtonSHughesRByasJ,et al.Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates. Antimicrob Agents Chemother2002; 46: 2007–2009.
114.
Perez-SantonjaJJKilvingtonSHughesR,et al.Persistently culture positive Acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. Ophthalmology2003; 110: 1593–1600.
115.
DartJKGSawVPJKilvingtonS. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol2009; 148: 487–499.
LimNGohDBunceC,et al.Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol2008; 145: 130–135.
BaggaBSharmaSGourRPS,et al.A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis. Eye (Lond)2021; 35: 1326–1333.
120.
Behrens-BaumannWSeiboldMHofmüllerW,et al.Benefit of polyhexamethylene biguanide in fusarium keratitis. Ophthalmic Res2012; 48: 171–176.
121.
LinHCHsiaoCHMaDH,et al.Medical treatment for combined Fusarium and Acanthamoeba keratitis. Acta Ophthalmol2009; 87: 199–203.
122.
DasSSahuSKSharmaS,et al.Clinical trial of 0.02% polyhexamethylene biguanide versus placebo in the treatment of microsporidial keratoconjunctivitis. Am J Ophthalmol2010; 150: 110–115.e2.
123.
RoozbahaniMHammersmithKMRapuanoCJ,et al.Therapeutic penetrating keratoplasty for acanthamoeba keratitis: a review of cases, complications and predictive factors. Int. Ophthalmol2019; 39: 2889–2896.
124.
Di ZazzoAKheirkhahAAbudTB,et al.Management of high-risk corneal transplantation. Surv. Ophthalmol2017; 62: 816–827.
125.
VaracalliGDi ZazzoAMoriT,et al.Challenges in Acanthamoeba keratitis: a review. J Clin Med2021; 10: 942.
126.
ODAK Phase 3. Comparing topical (eye drop) PHMB 0.08% only to PHMB 0.02% with propamidine 0.1% combination therapy for Acanthamoeba keratitis. ISRCTN registry. ISRCTN12199908. Available at: https://doi.org/10.1186/ISRCTN12199908(accessed on 12 September 2021).
127.
LiuNHKhongDChungSK,et al.In vitro susceptibility of ocular bacterial and fungal pathogens to polyhexamethylene biguanide. Invest Ophthalmol Vis Sci1996; 37: 4058.
128.
FiscellaRGMoshifarMMessickCR,et al.Polyhexamethylene biguanide (PHMB) in the treatment of experimental fusarium keratomycosis. Cornea1997; 16: 447–449.
129.
PinnaADonaduMGUsaiD,et al.In vitro antimicrobial activity of a new ophthalmic solution containing hexamidine diisethionate 0.05% (keratosept). Cornea2020; 39: 1415–1418.
